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Abstract
Background: Conflicting results on the correlation between hyperuricemia and the prognosis of stroke had been
reported and the close association between serum uric acid (SUA) and abnormal glycomatabolism might further
complicate the assessment of the correlation. We aimed to investigate SUA in predicting the prognosis of acute
stroke in different glycometabolism status.
Methods: A total of 2907 patients aged from 18 to 85 (1220 diabetes mellitus (DM), 777 prediabetes and 910
normoglycemia) were selected from the Abnormal Glucose Regulation in Patients with Acute Stroke across China
(ACROSS-China) study. The patients were divided into groups according to the SUA quartile as well as decile. The
correlations between SUA and the poor outcome (mRS > 2) at discharge were assessed stratified by glucose
metabolism status. Multivariate logistic regression was used to analyze the potential risk factors of poor in-hospital
outcome of stroke and the risk-adjustment of the correlation between SUA and the prognosis of stroke. P < 0.05
was considered statistically significant.
Results: SUA were divided first as Quartile1 to 4 (Quartile1 < 221 μmol L−1; Quartile2 (221–286) μmol L−1; Quartile3
(286–352) μmol L−1 and Quartile4 > 352 μmol L−1), then as decile1 to 10. In normoglycaemia, SUA quartiles, deciles
and continuous SUA concentration were independently significantly associated with poor outcome. Q1 was
independently associated with the higher possibility of poor functional outcome (compared to Q4, odds ratios
(ORs) with 95% confidential interval (CI) was 3.79 (1.23–8.67) in Q1); Lower level of SUA in DM was also associated
with poor functional outcome at discharge compared to the highest level of SUA(Q4)(OR with 95% CI, 2.07 (1.05–4.
08)), however, lower SUA level was also related to severer stroke at admission in DM as well as in prediabetes
(P < 0.001 in DM and 0.023 in prediabetes) and severer stroke resulted in worse functional outcome at discharge
(OR with 95% CI, 12.15 (8.08–18.21) in DM and 11.58 (7.50–23.25) in prediabetes). But in normoglycamic stroke, SUA
levels did not differ in stroke severity at admission (P = 0.066).
Conclusions: Low SUA level (<221 μmol L−1) independently and strongly predicts the short-term poor functional
outcome in acute stroke with normoglycaemia other than diabetes or prediabetes.
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Background
The association between hyperuricemia and cardiovas-
cular disease has been well documented for a very long
time. However, conflicting results on the correlation be-
tween hyperuricemia and the incidence and prognosis of
stroke had been reported. In a meta-analysis study, Kim,
et al. reported that hyperuricemia increased the risk of
both the ischemic stroke and the hemorrhagic stroke as
well as the risk of post-stroke mortality [1]. Several other
groups also found that the post-stroke hyperuricemia
could significantly exacerbate the outcome of stroke
[2–4]. Other study suggested that the effect of pre-
stroke hyperuricemia on poor post-stroke outcome, es-
pecially in diabetic patients, was still questionable [5].
Holme and his group also suggested that hyperuricemia
might be rather a complementary indicator than an in-
dependent risk factor of AS [6]. Kramer et al. found
that the importance of the pre- cardiovascular disease
hyperuricemia in predicting cardiovascular disease
mortality was only significant in the pre-diabetic and
type 2 diabetic patients but not in the normoglycemic
patients [7]. Some investigators even found that post-
stroke hyperuricemia might have played a protective role
in the prognosis of stroke [8–12]. Miedema et al. found
no evidence to support the association between the SUA
level and the outcome of stroke in their study [13].
Hyperuricemia, hyperglycaemia and cardiovascular dis-
ease are found to be co-morbid disease [14]. Hyperuricae-
mia is also positively associated with prediabetes diagnosed
according to impaired fasting glucose criteria other
than subjects with normal fasting glucose [15]. A meta-
analysis also ascertain that hyperglycaemia is contrib-
uted to the development of diabetes and impaired
fasting glucose [16]. Even in normal range of SUA, uric
acid is related to diabetes onset in healthy lean women
[17]. Since the close and complicated association be-
tween SUA and prediabetes as stated above and dia-
betes was a well-known risk factor of stroke [18], it is
in very need to assess and compare the effect of SUA
on stroke prognosis stratified by different glycometabo-
lism status. Newman et al. reported that a combination
of the post-stroke hyperuricemia and diabetes could
significantly increase the risk of adverse events, includ-
ing recurrent stroke, cardiovascular events even death,
in post-stroke patients [3]. In another study, Zhang
et al. found that the post-stroke hyperuricemia was as-
sociated with better short-term outcome of stroke in
non-diabetes patients [12]. However they failed to
distinguish between the pre-diabetes and the normogly-
cemia patients in their study. In our study, the associ-
ation between SUA and the outcome of acute primary
stroke would be assessed in both diabetes and normo-
glycemia patients. The pre-diabetes patients were ex-
cluded in our study.
Methods
Patient selection
ACROSS-CHINA” was a large prospective cohort
study conducted in China from 2008 to 2009 that in-
vestigated on abnormal glucose regulation in acute
first-ever stroke (within 14 days), in which a total of
3450 patients with ischemic stroke, intracerebral
hemorrhage (ICH) or subarachnoid hemorrhage (SAH)
were successively recruited from 34 hospitals across
China [19, 20]. Acute stroke was diagnosed according
to World Health Organization combined with CT or
MRI confirmation [21].
All the patients without previous DM were required to
perform a standard oral glucose tolerance test (OGTT)
at the day 14 ± 3 after stroke onset or before discharge
according to the World Health Organization criteria
[22]. Patients were categorized as diabetes, pre-diabetes
or normoglycemia according to their OGTT results.
One hundred and forty-four patients without SUA values
and 399 patients with missing OGTT results were ex-
cluded respectively. In the remaining 2,907 patients,
there were 1220 diabetics, 777 prediabetics and 910
normoglycaemic patients (Fig. 1).
Data collection
Demographic, education degree, tobacco use and alco-
hol consumption, physical exam and a National Institute
of Health Stroke Scale (NIHSS) score were obtained at
admission. A detailed history of previous diseases, such as
hypertension, coronary artery disease and atrial fibrilla-
tion, were also recorded. Body mass index (BMI) was
Fig. 1 Flow chart of patient selection. OGTT, oral glucose tolerance test
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defined as body weight (kg)/the square of height (m).
Participants without a history of diabetes were required to
take an OGTT test within 24 h after the hospital ad-
mission. The lab tests included blood routine test, high
density lipoprotein, low density lipoprotein, creatinine,
SUA, homocysteine, glucose and insulin level, et al. All
the lab tests were performed within 24 h after admis-
sion at fasting condition by the certified central labora-
tory. SUA was measured by the urine enzyme endpoint
method. The index of insulin resistance was calculated
with the Homeostasis Model Assessment 2- Insulin
Resistance (HOMA2-IR) method [23]. A Modified
Rankin Scale (mRS) was calculated in every participant at
discharge to evaluate the in-hospital outcome of stroke.
The criteria of diagnosing abnormal glycometabolism
The OGTT result and the blood glucose level were used
to divide patients into three categorise based on the
1999 World Health Organization (WHO) criteria. The
details were as follow: (1) Diabetes mellitus (DM) was
defined as fasting plasma glucose (FPG) ≥ 7.0 m mol L−1
and/or 2-h value (2-h-value) ≥ 11.1 m mol L−1; (2) Pre-
diabetes consisted of both impaired glucose tolerance
(IGT) and impaired fasting glucose (IFG). IGT was de-
fined as FPG < 7.0 m mol L−1 and a 2-h-value between
7.8 mmol/L and 11.1 m mol L−1. IFG was defined as
fasting glucose value between 6.1 m mol L−1 and
7.0 m mol L−1 with a normal 2-h-value; (3) normogly-
cemia was defined as FPG < 6.1 m mol L−1 and a 2-h-
value < 7.8 m mol L−1. Patients who had a history of DM
or had ever received hyperglycemic agents for at least
6 months were also assigned to the DM group. All the
prediabetics were newly-diagnosed.
Other variables definition
Tobacco use was categorized as ‘current’, ‘previous’ or
‘never’ smoking. ‘Current smoking’ was defined as that
the individual was an active smoker at the time of the
stroke. ‘Previous smoking’ was defined as that the indi-
vidual had quit smoking 1 year prior to the stroke.
‘Never smoking’ was defined as that the individual had
never smoked prior to the stroke. Alcohol consumption
was categorized as ‘never drinking’, ‘mild drinking’,‘mode-
rate to severe drinking’. ‘Moderate or severe drinking’ was
defined as that the individual consistently consumed ≥2
standard size alcoholic beverages per day. ‘Mild drinking’
was defined as that the individual consumed <2 standard
size alcoholic beverages per day. ‘Never drinking’ was
defined as that the individual had never consumed any
alcoholic beverages. Stroke severity was categorized by the
NIHSS score as mild stroke (NIHSS < 9) or severe stroke
(NIHSS ≥ 9) [4].
Outcome assessment
The primary endpoint comprised death and dependency
with mRS >2 [24, 25]. Death (mRS = 6) was recorded
within 14 ± 3 days after admission to the hospital.
Dependency (mRS = 3 to 5) was assessed at 14 ± 3 days
after the index date of hospital admission or at hospital
discharge. Death indicated all-cause death according to
the International Classification of Diseases, 10th Revi-
sion. Neurological improvement and deterioration
were used as supplemental indicators to describe the
association between SUA and stroke outcome. Neuro-
logical improvement was defined as 4 point decrease
in NIHSS during hospitalization or a 0 point status on
NIHSS at discharge. Neurological deterioration was
defined as 1 point increase in NIHSS during hos-
pitalization [24, 26, 27].
Statistical analysis
Baseline clinical features were compared stratified by
different diabetes diagnosis and functional outcome. All
continuous variables were presented as mean ± standard
deviation for normal distribution and median (Quartile 1
to 3) for skewed distribution. Kolmogorov-Smirnov test
was used for normal distribution test. Categorical vari-
ables were presented as frequencies and/or prevalence/
incidence rate. For the continuous variables, when the
group numbers were more than two, if the variable was
normal distribution, one-way ANOVA test was used to
perform the comparison (LSD-test for variables with
homogeneity of variance and Games-Howell test for
variables with heterogeneity of variance), otherwise
Kruskal-Wallis H test was performed instead; when the
group numbers were just two, if the variable was normal
distribution, T-test was used to perform the comparison,
otherwise Mann–Whitney U test was used instead. For
categorical variables, the comparisons were used Chi-
square test and Fisher exact test. The adjustment of the
correlation between different variables was done by
multivariate logistic regression. Variables with a P
value < 0.1 in univariate analysis were included in the
multivariate regression test. Variables, which had shown
potential association to the outcome of stroke during
the literature search, were also included in the multi-
variate regression test. The independent factors in-
cluded in the multivariate analysis were age, gender,
education degree, tobacco use, alcohol consumption,
BMI, high density lipoprotein, low density lipoprotein,
creatinine, systolic and diastolic blood pressure,
HOMA2-IR, homocysteine, a history of coronary heart
disease, a history of hypertension, a history of atrial
fibrillation, stroke types and stroke severity at admis-
sion. The use of Aspirin, Diuretics and Coumadin [28],
which could influence SUA concentration, were also
analyzed. SUA was compared between “use” and “non-
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use” of them respectively and stratified by different glyco-
metabolism first, then it will be recognized as a confound-
ing factor if P < 0.05 and entered into the according
multivariate analysis. The fitness of the models was evalu-
ated by using the Hosmer and Lemeshow goodness-of-fit
test and a P value > 0.2 was considered as a good fit. All
the statistical analyses were done with SPSS ver. 19.0 soft-
ware (SPSS Inc., Chicago, IL). A P <0.05 was considered
statistically significant.
Results
Comparison of the characteristics of patients in different
glucose metabolism groups
Patients with normoglycemia accounted for 31.3% of the
study population. The differences in the characteristics of
patients among different groups were shown in Table 1.
The normoglycemia group had highest percentage of
males (67.7% vs. 64.5%vs. 58.3%, P < 0.001) and higher
prevalence of current smoking (P = 0.036). The mean level
of age in this group was significantly younger than that of
the DM or prediabetes group (P < 0.001). In the physical
exam and the lab test, the patients in the normoglycemia
group had significantly lower blood pressure, BMI, NIHSS
score, low density lipoprotein level and HOMA2-IR than
that in the DM or prediabetes group (all P < 0.05). The
high density lipoprotein, homocysteine in the normo-
glycemia group were significantly higher than that in
the DM or prediabetes group (all P < 0.05). Previous
histories of coronary heart disease, hypertension or
atrial fibrillation in thenormoglycaemia group were
significantly less common than that in the DM group
(all P <0.05). Ischemic stroke was the most common
type of stroke in all groups, followed by intracerebral
hemorrhage and SAH. The percentages of stroke types
Table 1 Baseline Clinic features according to glycometabolism diagnosis by OGTT
Clinic features Diabetes mellitus (n = 1220) Prediabetes (n = 777) Normoglycemia (n = 910) P
Age, y (median, Q1–3) 64 (55, 73) 61 (52,72) 58 (49, 69)) <0.001
Male, n (%) 711(58.3) 501 (64.5%) 616 (67.7) <0.001
Tobacco use, n (%) 0.036
Never 712 (58.4) 428 (55.1) 480 (52.7)
Quit 110 (9.0) 74 (9.5) 79 (8.7)
Current 351 (28.8) 246 (31.7) 320 (35.2)
Alcohol consumption, n (%) 0.164
Mild 213 (17.5) 132 (17.0) 171 (18.8)
Moderate to severe 165 (13.5) 131 (16.9) 152 (16.7)
Never 817 (67.0) 494 (63.6) 564 (62.0)
BMI, kg/m2 (median, Q1–3) 25.0 (22.9,27.3) 24.5 (22.5,26.8) 24.2 (22.0,26.2) <0.001
NIHSS (median,Q1-Q3) 5 (2–9) 5 (2,9) 4 (2–8) 0.002
Creatinine,m mol L−1 (median, Q1–3) 71.2 (58.0, 87.0) 72.0 (60.0, 87.0) 71.8 (59.9, 86.7) 0.425
LDL, m mol L−1 (median, Q1–3) 3.0 (2.4, 3.6) 2.9 (2.3, 3.5) 2.8 (2.3, 3.4) 0.001
HDL,m mol L−1(median, Q1–3) 1.1(1.0, 1.3) 1.2 (1.0, 1.4) 1.2 (1.1, 1.4) <0.001
Systolic blood pressure, mmHg (median, Q1–3) 150 (138, 160) 143 (130, 160) 146 (130, 160) <0.001
Homocysteine, μ mol L−1, (median, Q1–3) 14.4 (11.5, 18.7) 15.5 (12.0, 21.9) 15.7 (12.3, 22.8) <0.001
HOMA2-IR (median, Q1–3) 2.5 (1.6, 4.0) 1.9 (1.1, 3.0) 1.6 (0.9, 2.5) <0.001
Past medical history, yes, n (%)
Coronary artery disease 172 (14.1) 87 (11.2) 90 (9.9) 0.009
Hypertension 795 (65.2) 470 (60.5) 514 (56.5) <0.001
Atrial fibrillation 66 (5.4) 54 (6.9) 31 (3.4) 0.006
Stroke types, n (%) <0.001
IS 1015 (83.2) 541 (69.6) 675 (74.2)
ICH 174 (14.3) 185 (23.8) 198 (21.8)
SAH 31 (2.5) 51 (6.6) 37 (4.1)
OGTT the oral glucose tolerance test, BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein, NIHSS the National Institutes of Health
Stroke Scale, HOMA2-IR the correctly solved computer model for homeostasis model assessment of insulin resistance, IS ischemic stroke, ICH intra-cerebral
hemorrhage, SAH subarachnoid hemorrhage
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were significantly different in patients with different
glycometabolism status (P <0.001).
Comparison of the characteristics of patients with
different functional outcomes of the stroke
There were no significant differences between the fa-
vorable outcome group and the poor outcome group
in the mean level of age, BMI, HOMA2-IR, low dens-
ity lipoprotein level, high density lipoprotein level, the
prevalence of the histories of coronary heart disease or
hypertension. Compared to the favorable outcome
group, the mean level of creatinine was significantly
lower in the poor outcome group, whereas the blood
pressure and homocysteine level were significantly
higher in the poor outcome group. The percentage of
moderate to severe alcohol consumption as well as the
percentage of severe stroke and atrial fibrillation in
the poor outcome group was significantly higher than
that in favorable outcome group. The percentage of
mild drinking was significantly higher in favorable
outcome group than that in the poor outcome group.
Ischemic stroke was the most common type of stroke
in both groups. Cardioembolic ischemic stroke was
only accounted for 5.7% (n = 91) of the total patients
with poor functional outcome. The intracerebral
hemorrhage was more commonly seen in the poor
outcome group than that in the favorable outcome
group while ischemic stroke and SAH were more
prevalent in the favorable outcome group. DM was
more prevalent in the poor outcome while normogly-
cemia were more commonly seen in the favorable out-
come group (Table 2).
Analysis on medication use and SUA concentration
There are 1542 patients with data on aspirin, 20 patients
on Coumadin and 124 patients on Diuretics. SUA levels
were compared between “use” and “non-use” of them re-
spectively and stratified by different glycometabolism.
After that a significant association was found between
Aspirin use and SUA level among normal glycemic
stroke patients (Additional file 1: Table S3, Additional
file 2: Table S4 and Additional file 3: Table S5). Aspirin
use was then entered into the multivariate analysis on
SUA and the outcome among normoglycaemic stroke
patients.
Correlation between SUA and poor functional outcome
at discharge
Univariate analysis of SUA quartiles on poor outcome
The patients were divided into quartile groups (Q1 to
Q4) based on their SUA level. The concentrations of
SUA in these groups were as follow: Q1 < 221 μmol L−1,
Q2 221-286 μmol L−1, Q3 286-352 μmol L−1 and Q4 >
352 μmol L−1 (DM group, NQ1=307, NQ2 = 306, NQ3 =
310, NQ4 = 291; Prediabetes group, NQ1=184, NQ2 = 198,
NQ3 = 190, NQ4 = 198; Normoglycaemia group, NQ1=229,
NQ2 = 218, NQ3 = 211, NQ4 = 248). In both diabetic and
normoglycemic strokes, the occurrence of stroke poor
outcome decreased across the increasing SUA levels
from Q1 to Q4(P = 0.019 in DM, 0.016 in normogly-
cemia), however, it didn’t differ in SUA quartiles in pre-
diabeteic strokes (P = 0.110 in prediabetes) (Fig. 2).
Multivariate analysis of SUA quartiles on poor functional
outcome at discharge
To further evaluate the correlation between the SUA
level and the poor post-stroke outcome, the SUA level
along with other potential risk factors of poor post-
stroke outcome were introduced into a regression model
as independent variables and the multivariate logistic
regression was used to assess the adjusted correlation
between the SUA level and the outcome of stoke. The
NIHSS score was entered into the regression model as
an ordinal variable with the cut-off point of 9 first and
then as a continuous one.
The final results of the regression showed that there
was a negative correlation between the SUA level and
the occurrence rate of poor outcome of stroke in
normoglycemic group. In the normoglycemic group, the
occurrence rate of poor outcome in Q1 group was also
significantly higher than that in the Q4 group (OR =
3.79, 95% CI 1.23–8.67, P =0.020) (Fig. 3); In DM group,
the possibility of poor outcome in lowest SUA group
(Q1) was significantly higher than that in Q4 (OR = 2.07,
95% CI 1.05–4.08). The possibility of poor outcome in
Q2 and Q3 groups were not significantly higher than
that in Q4 (Q2: OR = 1.33, 95% CI 0.71–2.47; Q3: OR =
1.79, 95% CI 0.99–3.26). In prediabetes, the possibility of
poor outcome did not differ in SUA quartiles (all P > 0.05).
The Hosmer and Lemeshow goodness-of-fit test results
(χ2, P) were (8.839, 0.356), (110.982, 0.215) and (4.558,
0.755) in the DM, prediabetes and the normoglycemia
group, respectively (Fig. 3).
In normoglycaemic stroke patients, NIHSS was then
entered as a continuous variable into multivariate ana-
lysis instead of NIHSS as a binary variable. The associ-
ation was still significant after the new adjustment
(Additional file 4: Table S7).
In normoglycaemic stroke patients, further analysis
was performed stratified by sex (Additional file 5:
Table S6). There was 620 male and 290 female in
normoglycaemic group. In male, after adjusted for the
same variables as the above, the lowest level of SUA is
still an independent risk factor for the poor functional
outcome (OR with 95% CI 5.06(1.17–12.05), P = 0.031).
However it was not the case in female patients (OR
with 95% CI 9.21(0.98–38.66), P = 0.158).
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Multivariate analysis of SUA deciles on poor functional
outcome
SUA was re-divided into decile groups (D1 to D10) in
different glucose metabolism groups. The SUA quartile
groups in previous regression model were replaced with
SUA deciles and a new regression model was calculated.
The ORs of the incidence rate of poor outcome obtained
from the regression model were used in the curve-fitting
Table 2 Baseline Clinic features according to poor functional outcomes evaluated by mRS > 2
Clinic features Favorable outcomes (n = 1305) Poor functional outcomes (n = 1602) P
Age, y 60 (52, 71) 62 (53, 72) 0.003
Male, n (%) 954 (73.1) 1089 (68.0) <0.001
Tobacco use, n (%) 0.036
Never 692 (53.0) 928 (57.9)
Quit 126 (9.7) 137 (8.6)
Current 436 (33.4) 481 (30.0)
Alcohol consumption, n (%) 0.006
Never 811 (62.1) 1064 (66.4)
Mild 266 (20.4) 250 (15.6)
Moderate to severe 192 (14.7) 256 (16.0)
BMI(kg/m2) 24.6 (22.5,26.7) 24.5 (22.4,26.8) 0.637
NIHSS scales <0.001
<9 1256 (96.2) 996 (62.2)
9–18 30 (2.3) 474 (29.6)
> 18 7 (0.5) 124 (7.7)
Creatinine (m mol L−1) 72.7 (60.0, 87.5) 70.0 (57.5,85.0) 0.002
LDL(m mol L−1) 2.8 (2.3,3.5) 2.9 (2.3,3.5) 0.290
HDL(m mol L−1) 1.2 (1.0,1.4) 1.2 (1.0,1.4) 0.125
Systolic blood pressure (mmHg) 140 (130,160) 150 (134,161) <0.001
Homocysteine (μmol L−1) 14.6 (11.4,19.8) 15.8 (12.3,21.4) <0.001
HOMA2-IR 1.8 (1.1,3.0) 2.0 (1.2,3.1) 0.055
Past medical history, yes, n (%)
Coronary heart disease 146 (11.2) 203 (12.7) 0.230
Hypertension 785 (60.2) 994 (62.0) 0.296
Atrial fibrillation 53 (4.1) 98 (6.1) 0.013
Stroke types, n (%) <0.001
Ischemic stroke 1059 (81.1) 1172 (73.2) <0.001
Cardioembolic 44 (3.4) 91 (5.7)
Large-artery atherosclerosis 565 (43.3) 819 (51.1)
Small-artery occlusion Lacunar 367 (28.1) 200 (12.5)
Other demonstrated or undemonstrated 38 (2.9) 25 (1.6)
ICH 176 (13.5) 381(23.8)
SAH 70 (5.4) 49 (3.1)
Glycometabolism status <0.001
Diabetes mellitus 500 (38.3) 720 (44.9)
Prediabetes 348 (26.7) 429 (26.8)
Normoglycaemia 457 (35.0) 453 (28.3)
mRS modified Rankin scale, BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein, NIHSS the National Institutes of Health Stroke Scale,
HOMA2-IR the correctly solved computer model for homeostasis model assessment of insulin resistance, IS ischemic stroke, ICH intra-cerebral hemorrhage,
SAH subarachnoid hemorrhage
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analysis. The curve-fitting results showed a U-shape
curve and the cubic curve had the highest R2 value in
both the DM group and the normoglycemia group
(Fig. 4a and c). The occurrence of poor outcome signifi-
cantly decreased across SUA deciles from D1 to D9 in
both normoglycemia and DM strokes (P for trend0.003
and 0.010, respectively), while it did not differ from D1-
10 in prediabetes group (Fig. 4 b, P for trend, 0.568).
Multivariate analysis of continuous SUA concentration on
poor functional outcome
SUA were further reintroduced into the multivariate
analysis as a continuous variable. After adjusting for
the same confounding factors as the above, higher
SUA was still significantly independently associated
with the less possibility of poor outcome in patients
with normoglycaemia, while the association did not
Fig. 3 Association between uric acid quartiles and poor outcomes in multivariate logistic regression analysis a (a adjusted for age, gender, stroke
types, tobacco use, alcohol consumption, education level received, a history of hypertension, coronary artery disease or atrial fibrillation, NIHSS <9
VS ≥9, body mass index, homocysteine, systolic blood pressure, diastolic blood pressure, HOMA-IR, low density lipoprotein, high density lipoprotein,
creatinine. In normoglycaemic subjects, Aspirin use was included as a binary variable in the analysis). NIHSS indicates the National Institutes of Health
Stroke Scale; HOMA2-IR indicates the correctly solved computer model for homeostasis model assessment of insulin resistance
Fig. 2 Poor outcome rates depending on serum uric acid quartiles stratified by glycometabolism status. OGTT, the oral glucose tolerance test. Q1-4
indicates serum uric acid levels by quartiles. Q1 to Q4 were Q1, <221 μmol L−1; Q2, (221–286) μmol L−1; Q3, (286–352) μmol L−1 and Q4, >352 μmol L−1
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exist in patients with DM or prediabetes (Table 3).
The Hosmer and Lemeshow goodness-of-fit test results
(χ2, P) were (9.873, 0.274) in DM, (4.719, 0.787) in predia-
betes and (5.621, 0.690) in normoglycemia group,
respectively.
SUA concentration and Neurological functional change
stratified by glycometabolism
SUA and Neurological improvement
In diabetic and prediabetic stroke patients, SUA quartiles
were significantly associated with neurological improve-
ment. Patients with the lowest level of SUA (<221umol/L)
occupied 28.5% and 30.6% within the diabetes and
prediabetes being neurological improved (both P <0.05.
Additional file 6: Table S1. Additional file 7: Figure S1).
SUA and Neurological deterioration
There were no significant association between SUA and
neurological deterioration in all the glycometabolism statuses
(Additional file 8: Table S2. Additional file 9: Figure S2).
Correlation between SUA levels and stroke severity at
admission
The correlation between stroke severity (NIHSS < 9,
9–18,>18) and the SUA level was also analyzed. The
patients were divided into 3 groups according to
NIHSS of <9, 9–18 and >18, respectively. The correl-
ation between stroke severity and the SUA quartile
was calculated (Fig. 5). In DM and prediabetes, the
percentage of patients with low SUA (Q1) in the se-
vere stroke group (NIHSS > 18) was significantly
higher than that in the mild stroke group (NIHSS < 9)
(P < 0.001for DM and 0.023 for prediabetes). There
were no significant differences in the SUA level across
Fig. 4 Association between serum uric acid deciles and poor outcomes in multivariate logistic regression analysisa (a adjusted for the same
variables as those in Fig. 3). *indicates the reference OR (the OR of D10 = 1). Reference point not included as basis for fit of regression lines.
D1-10 indicates 1st decile to the 10th decile of serum uric acid. D1 to D10 (μmol L−1) in ‘Diabetes’ were <169, 169–206, 206–235, 235–261,
261–286, 286–308, 308–334, 334–368, 368–424, >424. D1 to D10 (μmol L−1) in “Prediabetes” were <155, 155–208, 208–237, 237–266, 266–287,
287–314, 314–342, 342–380, 380–438, >438. D1-10 (μmol L−1) in ‘Normoglycaemia’ were <151, 151–201, 201–235, 235–260, 260–288, 288–316,
316–343, 343–381, 381–425, >425
Table 3 Association between SUA as a continuous variable and
poor outcome stratified by glycometabolism statusa
Glycometabolism status Odds ratio with 95%
confidence intervals
P
Diabetes mellitus 0.98 (0.97–1.00) 0.135
Prediabetes 1.00 (1.00–1.01) 0.105
Normoglycaemia 0.99 (0.98–1.00) 0.022
aadjusted for the same variables as those in Fig. 3
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different stroke severity in the normoglycemia group
(P = 0.066).
Other variables associated with the poor functional
outcome of the stroke in multivariate analysis
NIHSS ≥9 was a significant risk factor of the poor outcome
in all patients (In diabetes, 12.15 (8.08–18.21); In prediabe-
tes, 11.58 (7.50–23.25); In normoglycemia, 18.40 (7.90–
25.45)). In normoglycemia group, higher BMI as well as
higher systolic blood pressure were also related to signifi-
cantly higher risk of poor outcome (BMI 1.09 (1.02–1.18),
systolic blood pressure 1.02 (1.01–1.18)).
Discussion
Most of previous studies suggested that hyperuricemia
was a risk factor of stroke. In the present study, SUA
values in predicting poor functional outcomes after
stroke differed in 3 glycometabolism statuses. Lower
SUA level (SUA < 220 μmol L−1) was an independent
risk predictor of the short-term prognosis of the acute
first-ever stroke in patients with normoglycemia other
than DM or prediabetes and such an effect might has
gender difference. In the present study, the relationship
is much more robust in male than in female normogly-
caemic stroke patients.
Difference in the association of SUA level and post-stroke
poor functional outcome among different glycometabolism
status
The correlation between the SUA level and the poor
post-stroke outcome in the normoglycemia patients was
different from that in the DM or prediabetes patients in
our study. Low SUA level was an independent predictor
of the poor outcome of stroke in the normoglycemia pa-
tients but not in DM or prediabetes group. In DM
group, a paradox association was found: 1) the associ-
ation between the lowest SUA quartile (Q1) and the
poor outcome was observed as significant (Fig. 3. P =
0.032) but the trend from Q1-Q4 was not (Fig. 3. P for
trend = 0.109); 2) the association between SUA deciles
and poor outcome was in a significant trend (Fig. 4 a. P
for trend 0.003); 3) however, the significant association
disappeared when assessment was performed between
the continuous SUA concentration and the poor out-
come (Table 3 . P = 0.135). In prediabetes group, possi-
bility of poor outcome in the lower SUA levels was
similar to that in the higher SUA levels either SUA was
introduced into the multivariate analysis as a categorical
variable or a continuous variable.
These debated results might be attributed to the nega-
tive association between SUA levels and stroke severity
in DM and prediabetes (Fig. 5 a and b. P < 0.001 for DM
and 0.023 for prediabetes). The percentage of the lower
Fig. 5 Association between serum uric acid levels and stroke severity stratified by glycometabolism status. SUA indicates serum uric acid. NIHSS
indicates the National Institutes of Health Stroke Scale
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SUA level was significantly increased across the aggra-
vated stroke severity in diabetes and prediabetes group,
and stroke severity (measured as NIHSS level) was also
significantly associated with the poor outcome in the
multivariate analysis, we speculated that the effect of the
low SUA level in DM on the poor outcome of stroke
might be carried out via its correlation with the severity
of stroke. On the contrary, based on the fact that there
was no correlation between the SUA level and the severity
of stroke in normoglycemia patients (Fig. 5c. P = 0.066),
the association of SUA and poor outcome was inde-
pendent of stroke severity at baseline in normoglycemia
patients. Therefore, SUA in normoglycaemia was an in-
dependent risk factor of poor outcome, whereas SUA in
DM was only a complementary but not an independent
one.
Zhang et al. reported their findings of a similar study
in 2012 [12]. The correlation between the SUA level and
the poor outcome of stroke in patients with normogly-
cemia and DM in their study was in line with us;
Although the patients in their study were young and
mid-age adults (18–45 years old) which was different
with us (from 18 to 85 years old), the results were simi-
lar. It is a pity that they did not differentiate the predia-
betes patients from the ‘real’ normoglycemia patients.
Further than their research, we examine the association
in prediabetes. Though we did not found a significant
association between SUA and poor outcome in prediabe-
tes, concerning the results that the association was much
more significant and prominent in normoglycaemia pa-
tients than those with abnormal glycometabolism, it was
highly implied that glucose metabolism might deeply
affect the influence of SUA on post-stroke short-term
outcome.
Till now, the effect of SUA on the prognosis of
stroke in abnormal glucose metabolism is still debat-
able. Kramer et al. in their 2010 study reported that
hyperuricemia was a significant risk factor for the mor-
tality of cardiovascular disease in patients with pre-
diabetes and typeIIdiabetes, but it did not increase the
risk of mortality in patients with normoglycemia [7].
Their findings contradicted to our results. The con-
flicting results might be caused by the different race
(Caucasian vs. Chinese) and age (mid-age to elders vs.
18 to 85) of the participants as well as the different
sampling time of SUA (pre-event vs. post-event differ-
ent phases).
Gender difference is attributed to SUA concentra-
tion [29, 30], thus effect of SUA on poor functional
outcome differs in gender. There is no significant as-
sociation found in female subgroup in the present
study, which is mainly caused by the not large enough
sample size (only 290 female stroke patients with
normoglycaemia).
The possible mechanisms of the association between
post-stroke SUA levels and the outcomes after stroke
There were conflicting results about the association
between the post-stroke SUA level and the prognosis of
stroke in the literature. Several studies reported that
hyperuricemia was a risk factor for the poor outcomes
[2–4] and suggested that the follow adverse effects of
uric acid on the cardiovascular system might be the
underline reasons: first, Hyperuricemia could cause insu-
lin resistance [31]; second, hyperuricemia could increase
the risk of hypertension and further aggravated athero-
sclerosis [32]; third, hyperuricemia could directly or in-
directly impair the self-regulation of the arteriole and
increased the risk of stroke [33].
At the meanwhile, results from other studies suggested
hyperuricaemia might be a protective factor of stroke
[8–12, 34]. Most of them [8, 10–12, 34] were published
after the meta-analysis study from Kim, et al. [1]. In
another study, administration of uric acid during the
thrombolysis procedure in acute ischemic stroke patients
had been proven to be neuro-protective [35]. It had also
been proven in another study that low SUA was associ-
ated with larger infarction area and worse neurological
deficit in the stroke patients [36]. The possible mecha-
nisms of this protective effect of SUA included: (1) SUA
was one of the most important serum antioxidant fac-
tors and an anti-inflammatory factor [37–40]; (2) SUA
could stabilize endothelia progenitor cells (EPCs) [41];
(3) SUA could decrease the degradation of the extracel-
lular superoxide dismutase-3(SOD3) [42]; (4) In the
chronic disease, hyperuricaemia was a reaction of the
negative feedback mechanism to counterbalance the in-
creased level of reactive oxygen species (ROS) [43]. It
had been proven that Xanthine Oxidase (XO) expression
increased after acute ischemic cerebral lesion and the in-
creased XO would further lead to the uric acid level in
local brain tissue to increase significantly. The rate of
the change in XO and local uric acid level was positively
correlated with the severity of the ischemic damage of
the brain tissue [44, 45]. In 2010, Brouns, et al. reported
the rate of SUA decrease in the first 7 days after stroke
was positively correlated with the severity of the stroke
as well as the incidence rate of poor post-stroke out-
come [46]. Therefore, the concentration of peripheral
SUA post stroke is most possibly in a dynamically de-
creasing pattern but it is still unknown exactly.
This dynamically decreasing pattern of SUA post
stroke would attribute to the contradictory results on
SUA and poor outcome. Of all the researches, SUA
values from the different measurement timing post
stroke (some were within 3 days, some were within
14 days, others were within several hours, etc.) could
not stand for the SUA level in a concordant post-stroke
phase. Since its dynamic changes, the association of
Wu et al. BMC Neurology  (2017) 17:21 Page 10 of 12
SUA and poor outcome was altered concerning a spe-
cific population (poor outcome or favorable outcome).
For example, as for the patients with poor outcome,
when the timing of SUA evaluated was just at the phase
of higher SUA level, we might find an adverse effect of
SUA on poor outcome, otherwise the effect might find
to be protective. Therefore, the diverse investigations on
SUA at different phases post stroke might come to para-
dox results. Further investigation needs to be carried out
on figuring out the pattern of SUA concentration post
stroke and its association as well the abnormal glucose
metabolism on poor prognosis.
Advantages and limitations
ACROSS-CHINA is a nationwide, prospective, multiple-
center study. In our study, pre-diabetic patients were ex-
cluded by OGTT test result to eliminate their possible
interference to the results. There were some limitations
in our study. First, only patients with SUA data were in-
cluded in the study and this might cause selection bias.
Second, there were no data of the dynamic change of
SUA level. Third, only a few data on medications that
might affect the SUA level were collected and no data
on non-VKA oral anticoagulants (NOACs). Fourth, lack
of data on exercise pre- and post- stroke. Exercise is also
a major factor to influence SUA concentration [47].
Conclusions
The associations between post-stroke SUA and poor
functional outcome at discharge differ in diverse abnormal
glycometabolism populations. In acute stroke patients
with normoglycemia, low SUA level (<220 μmol L-1) is an
independent risk predictor of poor short-term outcome
other than DM or prediabetes. The debated conclusion on
the association between SUA and the poor outcome after
stroke might be due to the diverse post-stroke time of
blood sample for SUA in those different studies. Further
research will be conducted on the association between the
pattern of SUA change in stroke patients with different
time of stroke onset, different glycoemtabolism status,
different gender, through recording the dynamic value
of SUA post stroke and the poor functional outcome
and stratifying the study group by diagnosing glycome-
tabolism status.
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